Potent DNA Vaccine for MERS-CoV Shows Promise genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
DNA vaccine candidate induces potent immunity, offers protective efficacy in non-human primate models
A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen.
A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial. New results were published today in
JCI Insight.
While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic has emphasized.
The Wistar Institute
PHILADELPHIA (April 22, 2021) A synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV) developed at The Wistar Institute induced potent immune responses and afforded protective efficacy in non-human primate (NHP) models when given intradermally in abbreviated, low-dose immunization regimen. A similar vaccine candidate was previously shown to be safe and tolerable with a three-dose intramuscular injection regimen in a recently completed human phase 1 study and is currently in expanded studies of phase 1/2a trial.
New results were published today in JCI Insight.
“While several vaccine products are being advanced against MERS and other coronaviruses, low-dose delivery and shortened regimes are crucial to rapidly induce protective immunity, particularly during emerging outbreaks, as the current SARS-CoV-2 pandemic has emphasized,” said David B. Weiner, Ph.D., Wistar executive vice president, director of the Vaccine & Im
Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet Russian Direct Investment Fund 1305 Russian Direct Investment Fund 04 February 2021 11:42
In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results.
Efficacy of Sputnik V against COVID-19 was reported at 91.6%. Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
Sputnik V demonstrates 91.6% efficacy in Phase 3 trials - publication in The Lancet
MOSCOW. Feb 2 (Interfax) - Russia s Sputnik V coronavirus vaccine has demonstrated 91.6% efficacy in Phase 3 clinical trials, the Russian Direct Investment Fund (RDIF) said with the reference to the publication in The Lancet. Sputnik V s efficacy in fighting Covid-19 is validated by internationally peer reviewed data published in The Lancet. Efficacy of Sputnik V against Covid-19 was reported at 91.6%, RDIF said in a statement on Tuesday.
Data on 19,866 volunteers (14,954 of whom received the vaccine and 4,902 the placebo) was analyzed. The calculation is based on the analysis of 78 confirmed cases of Covid-19 (including 62 cases in the placebo group), it said.